Update in pathogenesis, diagnosis, and therapy of prolactinoma

N Fukuhara, M Nishiyama, Y Iwasaki - Cancers, 2022 - mdpi.com
Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Advances in the treatment of prolactinomas

MP Gillam, ME Molitch, G Lombardi… - Endocrine …, 2006 - academic.oup.com
Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Prolactinoma

P Chanson, D Maiter - The pituitary, 2022 - Elsevier
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical
attention and are an important cause of hypogonadism and infertility. The ultimate goal of …

Epidemiology and management challenges in prolactinomas

L Vroonen, AF Daly, A Beckers - Neuroendocrinology, 2019 - karger.com
Clinically relevant pituitary adenomas are present in about 1 per 1,000 of the general
population and prolactinomas are by far the most common clinical subtype of pituitary …

Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes

MJ Rutkowski, MK Aghi - Expert Review of Endocrinology & …, 2018 - Taylor & Francis
Introduction: Prolactinomas are unique tumors that may go into both hormonal and
radiographic remission with dopamine agonist therapy or transsphenoidal surgery …

Prolactin and reproductive medicine

JRE Davis - Current Opinion in Obstetrics and Gynecology, 2004 - journals.lww.com
Prolactin and reproductive medicine : Current Opinion in Obstetrics and Gynecology Prolactin
and reproductive medicine : Current Opinion in Obstetrics and Gynecology Log in or Register …

Medical treatment of prolactinomas

A Colao, S Savastano - Nature Reviews Endocrinology, 2011 - nature.com
Prolactinomas, the most prevalent type of neuroendocrine disease, account for
approximately 40% of all pituitary adenomas. The most important clinical problems …

Update on prolactinomas. Part 2: treatment and management strategies

A Wong, JA Eloy, WT Couldwell, JK Liu - Journal of Clinical neuroscience, 2015 - Elsevier
The authors present an update on the various treatment modalities and discuss
management strategies for prolactinomas. Prolactinomas are the most common type of …

Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature

R Sari, MA Altinoz, EBK Ozlu, A Sav… - Hormone and …, 2021 - thieme-connect.com
Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …

Long-term management of prolactinomas

JA Schlechte - The Journal of Clinical Endocrinology & …, 2007 - academic.oup.com
Prolactinomas are a frequent cause of gonadal dysfunction and infertility, especially in
young women. The regulation of prolactin secretion and the efficacy of dopamine agonists in …